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Inhibiting Integrin a5 Cytoplasmic Domain Signaling Reduces
Atherosclerosis and Promotes Arteriogenesis
Madhusudhan Budatha, PhD; Jiasheng Zhang, MD; Zhen W. Zhuang, MD; Sanguk Yun, PhD; James E. Dahlman, PhD; Daniel G. Anderson,
PhD; Martin A. Schwartz, PhD
Background-—Fibronectin in endothelial basement membranes promotes endothelial inﬂammatory activation and atherosclerosis
but also promotes plaque stability and vascular remodeling. The ﬁbronectin receptor a5 subunit is proinﬂammatory through binding
to and activating phosphodiesterase 4D5, which inhibits anti-inﬂammatory cyclic adenosine monophosphate and protein kinase A.
Replacing the a5 cytoplasmic domain with that of a2 resulted in smaller atherosclerotic plaques. Here, we further assessed plaque
phenotype and compensatory vascular remodeling in this model.
Methods and Results-—a5/2 mice in the hyperlipidemic apolipoprotein E null background had smaller plaques in the aortic root,
with reduced endothelial NF-jB activation and inﬂammatory gene expression, reduced leukocyte content, and much lower
metalloproteinase expression. However, smooth muscle cell content, ﬁbrous cap thickness, and ﬁbrillar collagen were unchanged,
indicating no shift toward vulnerability. In vivo knockdown of phosphodiesterase 4D5 also decreased endothelial inﬂammatory
activation and atherosclerotic plaque size. a5/2 mice showed improved recovery from hindlimb ischemia after femoral artery
ligation.
Conclusions-—Blocking the ﬁbronectin-Integrin a5 pathway reduces atherosclerotic plaque size, maintains plaque stability, and
improves compensatory remodeling. This pathway is therefore a potential therapeutic target for treatment of atherosclerosis. ( J
Am Heart Assoc. 2018;7:e007501. DOI: 10.1161/JAHA.117.007501.)
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A therosclerosis is an inﬂammatory disease of large tomidsized arteries that is induced by the convergence of
biomechanical, inﬂammatory, and metabolic risk factors
including disturbed ﬂuid shear stress, inﬂammatory cytokines,
oxidative stress, and high low-density lipoprotein choles-
terol.1-4 Despite medical progress, it remains the major
source of illness and death in developed nations.5,6
Atherosclerotic lesions preferentially develop at regions of
arteries where ﬂuid shear stress from blood ﬂow is lower and
undergoes complex changes in direction, termed disturbed
ﬂow. These ﬂow proﬁles are sensed by endothelial cells (ECs)
and trigger oxidative stress,7 NF-jB activation, and expression
of downstream genes including cytokines and leukocyte
recruitment receptors. This inﬂammatory “priming” sensitizes
these regions of arteries to systemic risk factors such as
hypercholesterolemia, diabetes mellitus, hypertension, and
smoking, to induce atherosclerotic plaques.8 These plaques
are characterized by accumulation of lipids, inﬂammatory cells
(monocytes, macrophages, and foam cells), cholesterol crys-
tals, proteoglycans, and extracellular matrix.5 Plaques that
become more inﬂamed, with large necrotic cores and thin
ﬁbrous caps, are prone to rupture, which triggers thrombosis
and vessel occlusion, the major source of mortality. Recent
studies have revealed that plaque vulnerability is also highly
correlated with low/disturbed ﬂow as well as collagen
degradation by matrix metalloproteinases (MMPs).9,10 Hence,
elucidating the mechanisms that govern plaque formation and
stability and vessel remodeling is an important goal.
EC inﬂammatory activation by disturbed ﬂow, oxidized
low-density lipoprotein, and IL-1b, which are major factors in
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atherosclerosis, is strongly modulated by the extracellular
matrix to which the cells adhere. Fibronectin (FN) through
its receptors, integrin a5b1 and avb3, enhances activation of
NF-jB and other inﬂammatory pathways in response to
disturbed ﬂow, oxidized low-density lipoproteins and IL-1b
to increase recruitment of inﬂammatory cells at atheroprone
sites, whereas the collagen/laminin receptor integrin a2b1
is anti-inﬂammatory.11,12 These effects were traced to
selective activation of the anti-inﬂammatory mediators cyclic
adenosine monophosphate (cAMP) and protein kinase A in
ECs on collagen or basement membrane protein but not
FN.7 The role of FN, however, is not entirely deleterious.
When plaque phenotype was examined after deletion of
plasma FN, plaques were smaller but appeared more
vulnerable, with thinner ﬁbrous caps, less collagen and
smooth muscle actin, and evidence of plaque rupture and
healing.13 Matrix remodeling therefore has complex effects
in plaque pathology.
To elucidate the role of integrin-speciﬁc signaling in these
processes, we created a chimeric integrin in which the
cytoplasmic domain of integrin a5 was replaced with that of
integrin a2 (a5/2 chimera). This receptor pairs with the b1
subunit and binds FN but signals as if bound to collagen,
activating cAMP and protein kinase A, and inhibiting NF-jB.14
a5/2 knock-in mice on the apolipoprotein E (ApoE/)
background had reduced atherosclerotic plaque size in the
aortic arch, supporting an inﬂammatory role for integrin a5.
These effects were linked to an interaction between a5
cytoplasmic domain and cAMP-speciﬁc phosphodiesterase
(PDE) 4D5. In the current study, we further investigate the
role of FN in atherosclerosis and vascular homeostasis by
more closely examining plaque phenotype and blood ﬂow
recovery in the integrin a5/2 mouse.
Materials and Methods
All data are available in the article. Reagents will be made
available upon reasonable request.
Mice
All mouse protocols were approved by the Yale University
Institutional Animal Care &UseCommittee. ApoEmice on a pure
C57BL6 background were purchased from Jackson Laboratory
(Bar Harbor, ME) and maintained in the colony. ApoE mice were
crossed with integrin a5/2 knock-in mice on a pure C57BL6
background. Age-matched, 8-week-old male mice were main-
tained on a Western diet (RD Western diet #D12079B, Open
Source Diet) for 4 weeks (wild-type [WT];ApoE/, n=5 mice;
a5/2;ApoE/ n=5 mice) or 16 weeks (WT;ApoE/ mice,
n=9; a5/2;ApoE/ mice, n=9) as indicated.
PDE4D small interfering RNA (siRNA) and control luciferase
siRNA packaged into endothelial speciﬁc nanoparticles were
administered intravenously via tail vein into WT (C57BL6) male
mice. Mouse aortas were isolated and intimal RNA prepared.
Quantitative real-time polymerase chain reaction analysis was
carried out for PDE4D and other inﬂammation markers as
described previously.14 For the atherosclerotic studies, 8-
week-old male ApoE/ mice were placed on a high-fat diet
and injected every 2 weeks with PDE4D or control siRNA for 4
injections in total. For all experiments, mice were euthanized
according to the Yale University Institutional Animal Care &
Use Committee–approved protocol. Mice were perfused with
4% paraformaldehyde via the left ventricle. The heart with
ascending aorta was dissected and ﬁxed overnight in 4%
paraformaldehyde and used for histological analysis.
Immunoﬂuorescence and Histochemistry
For cryosections, tissue was embedded in optimal cutting
temperature, frozen on dry ice, and stored at 80°C. Aortic
roots were sectioned on a cryostat to generate 10- to 15-lm
sections. Cryosections were ﬁxed in acetone for 10 minutes
at 20°C, blocked in IHC Tek antibody diluent (IHC World,
Ellicott City, MD) for 1 hour at room temperature, and
incubated with the indicated antibodies in IHC Tek antibody
diluent buffer. Antibodies were phospho-NFjB-P65 (1:100;
Cell Signaling Technology, Danvers, MA); FN (1:400; Sigma,
St. Louis, MO); VCAM-1 (1:200; BD Biosciences, San Jose,
CA); ICAM-1 (1:200; Biolegend, San Diego, CA); MMP9 (1:200;
Abcam, Cambridge, UK); MMP2 (1:300; Millipore, Burlington,
MA); CD45 (1:150; BD Pharmingen); CD68 (1:200; Abcam);
Clinical Perspective
What Is New?
• Fibronectin has been implicated in atherosclerosis, but
although it promotes inﬂammatory activation of the
endothelium and increases plaque size, it also promotes
plaque stability, most likely through its function as a
scaffold in collagen ﬁbril formation.
• The current study shows that mutating the cytoplasmic
domain of its receptor integrin a5, which blocks the
proinﬂammatory effect, reduces plaque size by inhibiting
binding to phosphodiesterase 4D5 and improves recovery
from hindlimb ischemia without impairing plaque stability.
What Are the Clinical Implications?
• These data indicate that a pathway involving integrin
a5-phosphodiesterase 4D5 signaling is a promising ther-
apeutic target for treating coronary and peripheral artery
disease.
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SMA (1:200; Sigma); F480 (1:200; Serotec, Hercules, CA).
Sections were washed 3 times in PBS and incubated with
Alexa ﬂuor 598-conjugated donkey anti-rabbit or -rat sec-
ondary antibody (Invitrogen, Carlsbad, CA) for 1 hour at room
temperature. Slides were washed with PBS and mounted in
Vectashield with DAPI (Vector Laboratories, Burlingame, CA).
Images were acquired using a Nikon 4 laser confocal
microscope. For histology, sections were stained with hema-
toxylin and eosin, Oil Red, or picrosirius red.
Quantiﬁcation and Statistical Analysis
ImageJ software (National Institutes of Health, Bethesda, MD)
was used for morphometric analysis. Mean lesion area and
necrotic core area in the aortic root (in mm2) were calculated
from the hematoxylin and eosin–stained aortic root sections.
All graphs were created using GraphPad Prism software (San
Diego, CA) and statistical analysis were performed using a
Student’s t test or a 2-way-ANOVA (multiple comparisons) as
described in GraphPad Prism 6. P values below 0.05 are
considered signiﬁcant.
Hindlimb Ischemia
Age-matched (12- to 14-week-old) WT (n=9) and a5/2 knock-
in mice (n=8) were subjected to femoral artery ligation, and
blood-ﬂow imaging was carried out by laser Doppler. Vascular
anatomy was analyzed by high-resolution micro-CT (GE
eXplore Locus SP, GE Healthcare, Chicago, IL) as described
previously.15,16
Results
Early Inﬂammatory Signaling in ApoE/ Mice
FN is deposited at atherosclerosis-prone regions in wild type
C57/Bl6 mice and increases as plaques develop in hyperlipi-
demic models.12 To examine the consequences of altered
a5b1 signaling in early plaque development, we maintained
WT;ApoE/ and a5/2;ApoE/ mice on a high-fat diet for
4 weeks and stained for FN and NF-jB target genes in the
aortic root. a5/2;ApoE/ mice showed reduced staining for
FN, the endothelial leukocyte recruitment receptor VCAM-1,
and inﬂammatory cells compared with WT;ApoE/ mice
(Figure 1). Thus, the a5 tail promotes high-fat diet–induced
inﬂammatory signaling at early stages of plaque formation.
Advanced Atherosclerotic Lesions in ApoE/
Mice
We next examined aortic root lesions in mice on a high-fat diet
for 16 weeks. Morphometric analysis of the hematoxylin and
eosin–stained aortic root showed a nearly 50% reduction in
aortic root area occupied by plaque in a5/2;ApoE/ mice
compared with WT;ApoE/ mice (Figure 2A), similar to what
was observed in the aortic arch.14 Further, plaques in a5/2;
ApoE/ had signiﬁcantly smaller necrotic cores compared
with WT;ApoE/ mice, and lipid staining with Oil Red O
showed similar reductions (Figure 2B). No differences in
plasma lipids or body weight were observed between WT and
a5/2 mice.14
NF-jB Activation and Leukocyte Accumulation
To gain further insight into the mechanisms involved, we
examined activation of NF-jB and induction of downstream
inﬂammatory genes in mice after 16 weeks of high-fat
feeding. Aortic root sections were stained for phosphorylated
NF-jB subunit p65, a step in NF-jB activation that accom-
panies nuclear translocation and promotes expression of
target genes. Phospho-p65 staining in the endothelial layer of
the aortic lesion was signiﬁcantly reduced in the a5/2;
ApoE/ compared with WT;ApoE/ mice (Figure 3A). The
leukocyte recruitment receptors ICAM1 and VCAM1, which
are induced in part through NF-jB, were signiﬁcantly reduced
in atherosclerotic lesions in the a5/2;ApoE/ compared
with WT;ApoE/ mice (Figure 3B and 3C). To test functional
consequences, we stained sections for markers of inﬂamma-
tory cells. CD45, a general marker for hematopoietic cells,
was signiﬁcantly reduced in a5/2;ApoE/ aortic root
sections (Figure 3D), as were the macrophage markers
CD68 (Figure 3E) and F4/80, a marker for mature macro-
phages (Figure 3F). Together, these results demonstrate that
the a5 tail promotes plaque expansion and inﬂammation.
Matrix Composition and Fibrous Cap Thickness
Inﬂammation and proteolysis of the extracellular matrix are
major contributors to plaque vulnerability.17,18 Plaque is
stabilized by a ﬁbrous cap, rich in smooth muscle cells and
collagen, and destabilized by inﬂammatory cells that produce
matrix-degrading metalloproteinases, principally MMP2 and
9.19-22 We therefore examined these components. When
ﬁbrillar collagen, a major determinant of tensile strength of
the plaque, was assessed by staining with picrosirius red,
there was no detectable difference between plaque in a5/2;
ApoE/ and ApoE/ mice (Figure 4A). FN staining was also
similar (Figure 4B), which may reﬂect its role in tissue repair
and remodeling through the TGFb23-25 and b-catenin path-
ways.26,27 By contrast, the major matrix-degrading enzymes,
MMP9 and MMP2, were signiﬁcantly reduced in the a5/2;
ApoE/ mice (Figure 4C and 4D). Vascular smooth muscle
cells synthesize a large fraction of the collagen in the ﬁbrous
cap and promote plaque stability.17,28,29 When smooth
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Figure 1. Inﬂammatory signaling in early atherosclerosis. Sections through the aortic root from ApoE/ and a5/2;ApoE/mice
on a high-fat Western diet for 4 weeks were stained for (A) ﬁbronectin (ApoE/ mice, n=5; a5/2;ApoE/ mice, n=5), (B) VCAM-1
(ApoE/ mice, n=4; a5/2;ApoE/ mice, n=4), (C) CD45 (ApoE/ mice, n=4; a5/2;ApoE/ mice, n=3), or (D) CD68 (ApoE/
mice, n=5; a5/2;ApoE/ mice, n=4). Nuclei were counterstained with DAPI (blue). Right, Quantiﬁcation of staining. Values are
meansSD (*P<0.05 comparedwith ApoE/; unpaired 2-tailed Student’s t test). APOE indicates ApoE; FN, ﬁbronectin;WT, wild type.
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Figure 2. Advanced atherosclerosis. Aortic roots from ApoE/ and a5/2;ApoE/ mice on a high-fat diet for 16 weeks. A, hematoxylin
and eosin–stained aortic root sections with quantiﬁcation of total plaque area (ApoE/ mice, n=9; a5/2;ApoE/ mice, n=9); and
necrotic core area (ApoE/ mice, n=9; a5/2;ApoE/ mice, n=9). Necrotic areas are highlighted with dotted blue lines. B, Oil Red staining
of aortic roots and quantiﬁcation of the stained area (ApoE/ mice, n=9; a5/2;ApoE/ mice, n=9). Values are meansSD (*P<0.05,
**P<0.01 compared with ApoE/; unpaired 2-tailed Student’s t test). APOE indicates ApoE; WT, wild type.
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muscle cell content was evaluated by staining for smooth
muscle actin, the staining in the plaque core, media, and
ﬁbrous cap showed no signiﬁcant difference between a5/2;
ApoE/ and WT;ApoE/ mice (Figure 5). Fibrous cap
thickness was also similar between WT and a5/2;ApoE/
mice. Mutation of the integrin a5 tail thus results in less
plaque with decreased inﬂammation and no evidence of
vulnerability.
Figure 3. Plaque inﬂammatory markers. Aortic roots from ApoE/ and a5/2;ApoE/ mice on a high-fat
diet for 16 weeks were stained for (A) phospho-S536 NF-jB p65 (ApoE/ mice, n=9; a5/2;ApoE/ mice,
n=9), (B) VCAM-1; (ApoE/ mice, n=9; a5/2;ApoE/ mice, n=9), (C) ICAM-1 (ApoE/ mice, n=7; a5/2;
ApoE/ mice, n=9), (D) CD45 (ApoE/ mice, n=8; a5/2;ApoE/ mice, n=9), (E) CD68 (ApoE/ mice,
n=9; a5/2;ApoE/ mice, n=9), and (F) F480 (ApoE/ mice, n=7; a5/2;ApoE/ mice, n=7). For
quantiﬁcation, values are meansSD (*P<0.05, **P<0.01 compared with ApoE/; unpaired 2-tailed
Student’s t test). Nuclei are counterstained with DAPI (blue).
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Figure 4. Matrix and matrix remodeling. Aortic root sections from ApoE/ and a5/2;ApoE/ mice on a high-fat diet for
16 weeks were stained as indicated, with nuclei counterstained with DAPI (blue). Adjacent graphs show quantiﬁcation as
meansSD. A, Picrosirius red (ApoE/ mice, n=6; a5/2;ApoE/ mice, n=6). B, Anti-ﬁbronectin (ApoE/ mice, n=9; a5/2;
ApoE/ mice, n=9). C, Anti-MMP9 (ApoE/ mice, n=9; a5/2;ApoE/ mice, n=8). D, Anti-MMP2 (ApoE/ mice, n=9; a5/
2;ApoE/ mice, n=9). NS, not signiﬁcant; ****P<0.0001; **P<0.005 compared with ApoE/; unpaired 2-tailed Student’s
t test). MMP indicates matrix metalloproteinase.
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In Vivo PDE4D Knockdown and Atherosclerosis
Our previous data implicated PDE4D5 as a binding partner
for the integrin a5 cytoplasmic domain that mediated the
proinﬂammatory effects of FN.14 We therefore investigated
whether its depletion in ECs in vivo reduced atherosclerosis.
siRNA packaged into nanoparticles speciﬁcally target the
endothelium without affecting hepatocytes, hematopoietic
cells, or other tissues.30 First, we evaluated the endothelial
in vivo knockdown of PDE4D and other proinﬂammatory
markers in intimal RNA, isolated from athero-prone regions
of WT mice injected with PDE4D or control luciferase siRNA,
as previously described.14 PDE4D siRNA greatly reduced the
mRNA levels of PDE4D, FN, VCAM, and MMP2 compared
with luciferase siRNA (Figure 6A). Next, ApoE/ mice on a
high-fat diet were treated with serial injections of PDE4D or
luciferase siRNA as outlined (Figure 6B). Intravenous injec-
tion of these particles had no effect on plasma low-density
lipoprotein cholesterol or triglycerides or on body weight
(Figure 6C). Examination of aortic roots in these mice after
8 weeks revealed signiﬁcantly reduced Oil Red O staining in
PDE4D- compared with control-injected mice (Figure 6D).
The NF-jB target genes VCAM1 and ICAM1, which in
luciferase siRNA-injected mice were elevated in atheroscle-
rotic plaques compared with uninvolved regions, were
signiﬁcantly reduced after PDE4D knockdown (Figure 7A
and 7B). PDE4D siRNA also reduced plaque staining for the
leukocyte markers CD45 and CD68 (Figure 7C and 7D).
These results are consistent with PDE4D5 as a downstream
effector for integrin a5 proinﬂammatory signaling in
atherosclerosis.
Hindlimb Ischemia in Integrin a5/2 Mice
The major mechanism for adaptation or recovery following
an arterial blockage by atherosclerotic plaque is compen-
satory remodeling. This process is triggered by elevated
shear stress in the small vessels parallel to the blocked
artery, resulting in their enlargement and arterialization, to
provide blood ﬂow to affected tissues downstream. To
compare responses of a5/2 and WT mice to arterial
blockage, femoral arteries were ligated. Blood ﬂow in the
lower limbs was then measured by laser Doppler imaging,
with blood ﬂow in the unaffected limb serving as a control.
These measurements showed that recovery of ﬂow was
accelerated in the a5/2 mice compared with WT (Figure 8A,
quantiﬁed in 8B). Next, we analyzed the remodeled vascu-
lature. Staining with platelet/endothelial cell adhesion
molecule antibody to mark capillaries in the lower leg at
21 days after surgery showed evidence of angiogenesis but
no signiﬁcant difference between WT and a5/2 mice
(Figure 9A). Next, larger vessels were visualized by micro
CT. In these experiments the vasculature is maximally
dilated prior to ﬁxation, followed by injection of contrast
agent and imaging. a5/2 mice had decreased vascular
density in both the thigh and calf regions compared with WT
mice (Figure 9B). To resolve the discrepancy, we also
stained for smooth muscle actin in sections from the
adductor muscle in the thigh to mark the arteries, ﬁxed
without prior dilation. Under these conditions, we observed
that the increase in artery diameter triggered by femoral
artery ligation was greater in the a5/2 mice (Figure 9C).
Together, these data suggest that a5/2 mice have improved
recovery from hindlimb ischemia (HLI) mainly due to
improved vessel function.
Discussion
Previous studies showed that genetic manipulations that
reduced FN in the vessel wall reduced atherosclerosis.
However, in the study that examined plaque phenotype,13
deletion of plasma FN resulted in thinning of the ﬁbrous cap and
plaque rupture, demonstrating that FN contributes to plaque
stabilization. Mechanistic work in our lab showed that the
major FN receptor, integrin a5, promotes inﬂammatory activa-
tion of ECs by binding PDE4D5. This interaction promotes
PDE enzymatic activity and inhibits the anti-inﬂammatory
Figure 5. Fibrous caps. Aortic root sections from WT;ApoE/
and a5/2;ApoE/ mice on a high-fat diet for 16 weeks were
stained for smooth muscle actin (SMA). Quantiﬁcation shows the
percentage of the plaque area stained positive for SMA (ApoE/
mice, n=7; a5/2;ApoE/ mice, n=9) and ﬁbrous cap thickness
(ApoE/ mice, n=8; a5/2;ApoE/ mice, n=9). Values are
meansSD (NS, Not signiﬁcant compared with ApoE/;
unpaired 2-tailed Student’s t test). APOE indicates ApoE; WT,
wild type.
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cAMP–protein kinase A pathway, thus sensitizing ECs to
inﬂammatory stimuli.14 This study also showed that replacing
the cytoplasmic domain of a5 with that of a2 in mice reduced
atherosclerotic plaque size in the aortic arch, supporting a role
in vivo. In the current study, we analyzed plaque phenotype in
greater detail in a5/2;ApoE/mice. We found that thesemice
Figure 6. Endothelial in vivo PDE4D5 knockdown. PDE4D siRNA or luciferase siRNA were packaged into endothelial-
speciﬁc nanoparticles and administered intravenously into WT (C57BL6) mice. A, Intimal RNA was isolated and assayed
for PDE4D and proinﬂammatory gene expression by quantitative real-time polymerase chain reaction. B, Outline of
PDE4D siRNA protocol for atherosclerosis. ApoE/ mice on a high-fat diet were serially injected with nanoparticle-
packaged PDE4D or luciferase siRNA and examined at 8 weeks. C, Plasma lipid levels. D, Aortic root sections were
stained for Oil Red O, and the positively stained area was quantiﬁed (siLUC; n=5 mice; siPDE4D, n=5 mice). *P<0.05
compared with ApoE/ by unpaired 2-tailed Student’s t test. FN indicates ﬁbronectin; HDL, high-density lipoprotein;
HFD, high-fat diet; LDL, low-density lipoprotein; LUC, luciferase; MMP, matrix metalloproteinase; PDE, phosphodi-
esterase; si, small interfering [RNA]; WT, wild type.
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Figure 7. In vivo PDE4D (4D5) knockdown and plaque inﬂammatory markers. ApoE/ mice on a high-fat diet were serially
injected with nanoparticle-packaged PDE4D or luciferase siRNA, and examined at 8 weeks. Aortic root sections were stained
for (A) VCAM-1 (siLUC, n=4 mice; siPDE4D, n=5 mice); (B) ICAM-1 (siLUC, n=4 mice; siPDE4D, n=4 mice); (C) CD45 (siLUC,
n=4 mice; siPDE4D, n=5 mice); and (D) CD68 (siLUC, n=5 mice; siPDE4, n=4 mice), as indicated. For quantiﬁcation, values
are meansSD *P<0.05 compared with ApoE/ by unpaired 2-tailed Student’s t test. LUC indicates luciferase; PDE,
phosphodiesterase; si, small interfering [RNA].
DOI: 10.1161/JAHA.117.007501 Journal of the American Heart Association 10
Integrin a5 in Atherosclerosis and Arteriogenesis Budatha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 25, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
had reduced early and late inﬂammatory activation in the vessel
wall and smaller plaques in the aortic root. Importantly, plaques
in these mice had lower MMP expression and maintained
ﬁbrous cap thickness. Endothelial-speciﬁc in vivo knockdown of
PDE4D5 also reduced plaque burden, supporting the notion that
this enzyme is an important mediator of the inﬂammatory,
proatherosclerotic effects of FN. However, maintaining knock-
down of the enzyme for longer periods is technically difﬁcult,
and the shorter time for these experiments precluded analysis
of plaque stability.
FN is well known to serve as a scaffold that promotes
collagen ﬁbrillogenesis.31,32 These results lead us to hypoth-
esize that FN has at least 2 distinct functional roles in
atherosclerosis. By binding integrin a5b1, it promotes
inﬂammatory signaling and favors progression of the
atherosclerotic plaque. However, through its role in collagen
ﬁbrillogenesis, FN also promotes plaque stability. Because
plaque rupture is thought to be the major cause of clinical
events, FN synthesis and matrix assembly are not attractive
therapeutic targets.
Results in the HLI model, however, support the a5-PDE-
cAMP pathway as a potential therapeutic target. These
experiments showed that blood ﬂow in the affected limbs of
a5/2 mice recovered more rapidly than in WT controls after
femoral artery ligation. This outcome is surprising in that
C57BL6 recover well from HLI and, indeed, have been used in
genetic studies as a prototypical high-responding strain.33,34
The improved recovery in a system where remodeling is
already rapid strongly encourages examining these effects in
genetic backgrounds and disease settings where recovery is
poor.
The second surprising result is that the improved ﬂow
recovery was associated with less rather than more vascu-
larization. Thus, blocking the FN- a5/2-PDE pathway does
not promote vessel remodeling per se. A more likely
explanation is that the a5/2 mutation improves vessel
function to allow higher blood ﬂow through the existing
vasculature. Indeed, when analyzed without prior vasodila-
tion, arteries in the upper leg in a5/2 mice had larger
diameters. A similar improved recovery from HLI while
decreasing vascular density as measured by microCT was
seen following EC-speciﬁc inhibition of NF-jB.16 Because
microCT is done in mice injected with a strong vasodilator
before ﬁxation, differences in vessel function would not be
detected. This idea is consistent with a report that plating
ECs on FN reduced endothelial nitric oxide synthase
activation and NO production, and that injection of an
antagonist of integrin a5 increased plasma nitrate levels in
mice.35 Whatever the mechanism, the improved blood ﬂow
recovery after HLI further supports the idea that blocking FN
signaling through a5 may be beneﬁcial in vascular disease.
The a5/2 chimera was a whole-animal knock-in; thus,
multiple cell types could contribute to the observed effects. In
vitro experiments with ECs showed reduced NF-jB activation
and inﬂammatory gene expression,14 which ﬁts well with
reduced inﬂammatory gene expression in the endothelium in
early atherosclerosis, supporting these cells as important
mediators. However, smooth muscle cells also show modu-
lation of inﬂammatory pathways by matrix proteins,36,37 as do
monocyte/macrophage lineages.38,39 Moreover, both of these
lineages play roles in both inﬂammatory processes and
ﬁbrous cap phenotype. Further work with tissue-speciﬁc
knock-in will be required to sort out these questions.
In conclusion, these results resolve the dual role of FN in
atherosclerosis by demonstrating that signaling through
integrin a5b1 mediates the proinﬂammatory effects but not
the effects on plaque stability. Proinﬂammatory signaling is
Figure 8. Blood ﬂow recovery after hindlimb ischemia. A,
Representative laser Doppler images of ﬂow in the hind limbs
before surgery and at the indicated times after femoral artery
ligation. B, Quantiﬁcation from multiple mice (WT mice, n=9; a5/2
mice, n=9). Values are meansSD. *P<0.05 by unpaired 2-tailed
Student’s t test. WT indicates wild type.
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mediated at least in part through PDE4D5. The data further
demonstrate that inhibiting FN-a5 signaling promotes recov-
ery from arterial restriction. Further study to determine
whether this pathway can serve as a therapeutic target in
atherosclerosis and possibly other chronic inﬂammatory
diseases therefore seems warranted.
Figure 9. Arterial vasculature after hindlimb ischemia. Analysis of vasculature in WT and mutant mice 21 days after
surgery. A, Sections through the calf region were stained with PECAM antibody (CD31) to mark blood vessels in the
lower leg. Capillary density was then quantiﬁed (WT mice, n=4; a5/2 mice, n=4). B, Representative microCT images of
vasculature. The number of vessels within each size range was quantiﬁed as described in Methods (WT mice, n=5; a5/
2 mice, n=5; *P<0.001 by 2-way ANOVA, multiple comparisons). C, Sections through the upper leg were stained for
smooth muscle actin to label arteries and vessel diameter measured (WT mice, n=4; a5/2 mice, n=4). For all panels,
values are meansSD. *P<0.05, **P<0.005 compared with WT mice by unpaired 2-tailed Student’s t test. CT indicates
computed tomography; Lig, ligated; PECAM, platelet/endothelial cell adhesion molecule; WT, wild type.
DOI: 10.1161/JAHA.117.007501 Journal of the American Heart Association 12
Integrin a5 in Atherosclerosis and Arteriogenesis Budatha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 25, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Acknowledgments
Lipid analysis was done by the Yale Mouse Phenotypic Center
supported by U24 DKO59635 grant. We are thankful to Rita Webber
and Nicole Copeland for maintaining the mouse colonies used in the
study. We thank Tristan Driscoll (Yale University) for advice about
statistical analysis.
Author Contributions
Budatha designed the study, performed all experiments, and
analyzed data except where otherwise noted, and wrote the
article. Zhang performed femoral artery ligation surgery.
Zhuang performed and analyzed microCT. Yun developed the
in vivo siRNA sequences. Dahlman carried out nanoparticle
packaging for in vivo knockdowns. Anderson supervised and
supported in vivo nanoparticle packaging. Schwartz initiated
and supervised the project, co-wrote the article, and provided
ﬁnancial support.
Sources of Funding
This work was supported by National Institute of Health (RO1
HL75092 and HL107205) to Schwartz.
Disclosures
None.
References
1. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of
atherosclerosis and the potential to reduce the global burden of atherothrom-
botic disease. Circ Res. 2016;118:535–546.
2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the
biology of atherosclerosis. Nature. 2011;473:317–325.
3. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden
coronary death: a comprehensive morphological classiﬁcation scheme for
atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–1275.
4. Tabas I, Garcia-Cardena G, Owens GK. Recent insights into the cellular biology
of atherosclerosis. J Cell Biol. 2015;209:13–22.
5. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ,
Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi
P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte
CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A,
Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J,
Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A,
Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW,
Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R,
Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to
vulnerable patient: a call for new deﬁnitions and risk assessment strategies:
Part II. Circulation. 2003;108:1772–1778.
6. Dave T, Ezhilan J, Vasnawala H, Somani V. Plaque regression and plaque
stabilisation in cardiovascular diseases. Indian J Endocrinol Metab.
2013;17:983–989.
7. Funk SD, Yurdagul A Jr, Green JM, Jhaveri KA, Schwartz MA, Orr AW. Matrix-
speciﬁc protein kinase A signaling regulates p21-activated kinase activation by
ﬂow in endothelial cells. Circ Res. 2010;106:1394–1403.
8. DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on
recurrence and survival—analysis of 11,890 cases with more than 25-year
follow-up. Am J Cardiol. 2000;85:1045–1053.
9. Papafaklis MI, Takahashi S, Antoniadis AP, Coskun AU, Tsuda M, Mizuno S,
Andreou I, Nakamura S, Makita Y, Hirohata A, Saito S, Feldman CL, Stone PH.
Effect of the local hemodynamic environment on the de novo development and
progression of eccentric coronary atherosclerosis in humans: insights from
PREDICTION. Atherosclerosis. 2015;240:205–211.
10. Andreou I, Antoniadis AP, Shishido K, Papafaklis MI, Koskinas KC, Chatzizisis
YS, Coskun AU, Edelman ER, Feldman CL, Stone PH. How do we prevent the
vulnerable atherosclerotic plaque from rupturing? Insights from in vivo
assessments of plaque, vascular remodeling, and local endothelial shear
stress. J Cardiovasc Pharmacol Ther. 2015;20:261–275.
11. Yurdagul A Jr, Green J, Albert P, McInnis MC, Mazar AP, Orr AW. a5b1 integrin
signaling mediates oxidized low-density lipoprotein-induced inﬂammation and
early atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:1362–1373.
12. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The
subendothelial extracellular matrix modulates NF-jB activation by ﬂow: a
potential role in atherosclerosis. J Cell Biol. 2005;169:191–202.
13. Rohwedder I, Montanez E, Beckmann K, Bengtsson E, Duner P, Nilsson J,
Soehnlein O, Fassler R. Plasma ﬁbronectin deﬁciency impedes atherosclerosis
progression and ﬁbrous cap formation. EMBO Mol Med. 2012;4:564–576.
14. Yun S, Budatha M, Dahlman JE, Coon BG, Cameron RT, Langer R, Anderson
DG, Baillie G, Schwartz MA. Interaction between integrin a5 and PDE4D
regulates endothelial inﬂammatory signalling. Nat Cell Biol. 2016;18:1043–
1053.
15. Conway DE, Coon BG, Budatha M, Arsenovic PT, Orsenigo F, Wessel F, Zhang J,
Zhuang Z, Dejana E, Vestweber D, Schwartz MA. VE-cadherin phosphorylation
regulates endothelial ﬂuid shear stress responses through the polarity protein
LGN. Curr Biol. 2017;27:2727.
16. Tirziu D, Jaba IM, Yu P, Larrivee B, Coon BG, Cristofaro B, Zhuang ZW, Lanahan
AA, Schwartz MA, Eichmann A, Simons M. Endothelial nuclear factor-jB-
dependent regulation of arteriogenesis and branching. Circulation.
2012;126:2589–2600.
17. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation.
1995;92:657–671.
18. Libby P. The molecular mechanisms of the thrombotic complications of
atherosclerosis. J Intern Med. 2008;263:517–527.
19. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells
from experimental atheroma constitutively produce matrix-degrading pro-
teinases. Proc Natl Acad Sci USA. 1995;92:402–406.
20. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix
metalloproteinases and matrix degrading activity in vulnerable regions of
human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503.
21. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Unemori EN, Lark
MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle
cells synthesize a complement of enzymes required for extracellular matrix
digestion. Circ Res. 1994;75:181–189.
22. Schneider F, Sukhova GK, Aikawa M, Canner J, Gerdes N, Tang SM, Shi GP,
Apte SS, Libby P. Matrix-metalloproteinase-14 deﬁciency in bone-marrow-
derived cells promotes collagen accumulation in mouse atherosclerotic
plaques. Circulation. 2008;117:931–939.
23. Ignotz RA, Endo T, Massague J. Regulation of ﬁbronectin and type I collagen
mRNA levels by transforming growth factor-b. J Biol Chem. 1987;262:6443–
6446.
24. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming
growth factor-beta increases steady state levels of type I procollagen and
ﬁbronectin messenger RNAs posttranscriptionally in cultured human dermal
ﬁbroblasts. J Clin Invest. 1987;79:1285–1288.
25. Ignotz RA, Massague J. Transforming growth factor-beta stimulates the
expression of ﬁbronectin and collagen and their incorporation into the
extracellular matrix. J Biol Chem. 1986;261:4337–4345.
26. Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer b-catenin controls
ﬁbronectin expression. Mol Cell Biol. 1999;19:5576–5587.
27. Gelfand BD, Meller J, Pryor AW, Kahn M, Bortz PD, Wamhoff BR, Blackman BR.
Hemodynamic activation of b-catenin and T-cell-speciﬁc transcription factor
signaling in vascular endothelium regulates ﬁbronectin expression. Arterioscler
Thromb Vasc Biol. 2011;31:1625–1633.
28. Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in
atherosclerosis. Circ Res. 2016;118:692–702.
29. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of ﬁbrous cap thickness
on peak circumferential stress in model atherosclerotic vessels. Circ Res.
1992;71:850–858.
30. Dahlman JE, Barnes C, Khan OF, Thiriot A, Jhunjunwala S, Shaw TE, Xing Y,
Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL, Yin H, Racie T, Dong Y,
Jiang S, Seedorf D, Dave A, Singh Sandhu K, Webber MJ, Novobrantseva T,
Ruda VM, Lytton-Jean AK, Levins CG, Kalish B, Mudge DK, Perez M, Abezgauz
L, Dutta P, Smith L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M,
Danino D, Tuder RM, von Andrian UH, Akinc A, Panigrahy D, Schroeder A,
Koteliansky V, Langer R, Anderson DG. In vivo endothelial siRNA delivery using
DOI: 10.1161/JAHA.117.007501 Journal of the American Heart Association 13
Integrin a5 in Atherosclerosis and Arteriogenesis Budatha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 25, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
polymeric nanoparticles with low molecular weight. Nat Nanotechnol.
2014;9:648–655.
31. Kadler KE, Hill A, Canty-Laird EG. Collagen ﬁbrillogenesis: ﬁbronectin,
integrins, and minor collagens as organizers and nucleators. Curr Opin Cell
Biol. 2008;20:495–501.
32. Kubow KE, Vukmirovic R, Zhe L, Klotzsch E, Smith ML, Gourdon D, Luna S,
Vogel V. Mechanical forces regulate the interactions of ﬁbronectin and
collagen I in extracellular matrix. Nat Commun. 2015;6:8026.
33. Chalothorn D, Clayton JA, Zhang H, Pomp D, Faber JE. Collateral density,
remodeling, and VEGF-A expression differ widely between mouse strains.
Physiol Genom. 2007;30:179–191.
34. Sealock R, Zhang H, Lucitti JL, Moore SM, Faber JE. Congenic ﬁne-mapping
identiﬁes a major causal locus for variation in the native collateral circulation
and ischemic injury in brain and lower extremity. Circ Res. 2014;114:660–671.
35. Yurdagul A Jr, Chen J, Funk SD, Albert P, Kevil CG, Orr AW. Altered nitric oxide
production mediates matrix-speciﬁc PAK2 and NF-jB activation by ﬂow. Mol
Biol Cell. 2013;24:398–408.
36. Orr AW, Lee MY, Lemmon JA, Yurdagul A Jr, Gomez MF, Bortz PD, Wamhoff BR.
Molecular mechanisms of collagen isotype-speciﬁc modulation of smooth
muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2009;29:225–231.
37. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and
function of the inﬂammatory smooth muscle cell phenotype in atherosclerosis.
J Vasc Res. 2010;47:168–180.
38. Roman J, Ritzenthaler JD, Fenton MJ, Roser S, Schuyler W. Transcriptional
regulation of the human interleukin 1b gene by ﬁbronectin: role of protein
kinase C and activator protein 1 (AP-1). Cytokine. 2000;12:1581–1596.
39. Reyes-Reyes M, Mora N, Gonzalez G, Rosales C. b1 and b2 integrins activate
different signalling pathways in monocytes. Biochem J. 2002;363:273–280.
DOI: 10.1161/JAHA.117.007501 Journal of the American Heart Association 14
Integrin a5 in Atherosclerosis and Arteriogenesis Budatha et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 25, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
G. Anderson and Martin A. Schwartz
Madhusudhan Budatha, Jiasheng Zhang, Zhen W. Zhuang, Sanguk Yun, James E. Dahlman, Daniel
Arteriogenesis
5 Cytoplasmic Domain Signaling Reduces Atherosclerosis and PromotesαInhibiting Integrin 
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.007501
2018;7:e007501; originally published January 30, 2018;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/7/3/e007501
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on A
pril 25, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
